Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$444K Hold
8,053
0.16% 103
2025
Q4
$485K Hold
8,053
0.17% 93
2025
Q3
$348K Sell
8,053
-100
-1% -$3.91K 0.13% 109
2025
Q2
$313K Hold
8,153
0.13% 114
2025
Q1
$316K Buy
8,153
+3,000
+58% +$110K 0.13% 105
2024
Q4
$174K Sell
5,153
-5,200
-50% -$187K 0.08% 140
2024
Q3
$423K Buy
10,353
+3,000
+41% +$123K 0.19% 78
2024
Q2
$283K Hold
7,353
0.14% 90
2024
Q1
$315K Sell
7,353
-750
-9% -$30.9K 0.16% 91
2023
Q4
$300K Buy
8,103
+2,684
+50% +$96.4K 0.16% 87
2023
Q3
$196K Hold
5,419
0.11% 106
2023
Q2
$193K Sell
5,419
-6,787
-56% -$243K 0.11% 110
2023
Q1
$434K Buy
12,206
+415
+4% +$14.5K 0.25% 68
2022
Q4
$414K Buy
11,791
+260
+2% +$8.66K 0.25% 73
2022
Q3
$339K Buy
11,531
+5,037
+78% +$191K 0.23% 75
2022
Q2
$353K Sell
6,494
-600
-8% -$33.1K 0.23% 78
2022
Q1
$386K Buy
7,094
+39
+0.6% +$2.12K 0.22% 75
2021
Q4
$389K Sell
7,055
-31
-0.4% -$1.61K 0.23% 72
2021
Q3
$338K Buy
7,086
+1,200
+20% +$60.3K 0.22% 73
2021
Q2
$293K Hold
5,886
0.21% 70
2021
Q1
$263K Buy
5,886
+100
+2% +$4.54K 0.2% 74
2020
Q4
$266K Buy
+5,786
New +$266K 0.24% 72

Other funds holding GSK

Sittner & Nelson's GSK Position: Q1 2026 in Review

Sittner & Nelson held its GSK (GSK) position steady in Q1 2026 at 8,053 shares worth $444K. The position accounts for 0.16% of the portfolio, ranked #103.

Sittner & Nelson first reported a position in GSK in Q4 2020 and has held it in 22 quarters since. The position peaked at $485K in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Sittner & Nelson held 8,053 shares of GSK worth $444K as of Q1 2026.
  • Sittner & Nelson left its GSK share count unchanged in Q1 2026.
  • GSK made up 0.16% of Sittner & Nelson's portfolio in Q1 2026, its #103 holding.
  • Sittner & Nelson first reported a position in GSK in Q4 2020 and has held it in 22 quarters since.
  • Sittner & Nelson's GSK position peaked at $485K in Q4 2025.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Sittner & Nelson's 13F filing for Q1 2026, filed 12 May 2026.